AstraZeneca PLC
ZEGA
Company Profile
Business description
A merger between Astra of Sweden and Zeneca Group of the United Kingdom formed AstraZeneca in 1999. The firm sells branded drugs across a number of major therapeutic areas, including oncology (about 40% of total revenue), cardiovascular, renal, and metabolic (25%), rare disease (17%), and respiratory and immunology (15%). The majority of sales comes from international markets, with the United States representing close to one third of its sales.
Contact
1 Francis Crick Avenue
Cambridge Biomedical Campus
CambridgeCB2 0AA
GBRT: +44 2037495000
Sector
Healthcare
Stock type
Defensive
Industry
Drug Manufacturers - General
Fiscal Year End
31 December 2025
Employees
94,300
Stocks News & Analysis
stocks
BlackRock earnings: Market gains and inflows drive AUM and revenue to record highs
We plan to raise our fair value estimate of BlackRock stock.
stocks
Our view of ANZ’s strategic plan
Trying to please customers and shareholders with a simpler and leaner bank.
stocks
Perplexing buyback from overvalued ASX share
Earnings continue to grow but investor expectations are too high.
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 9,271.60 | 5.50 | -0.06% |
| CAC 40 | 7,919.62 | 14.64 | -0.18% |
| DAX 40 | 24,236.94 | 150.99 | -0.62% |
| Dow JONES (US) | 46,270.46 | 202.88 | 0.44% |
| FTSE 100 | 9,452.77 | 9.90 | 0.10% |
| HKSE | 25,714.89 | 273.54 | 1.08% |
| NASDAQ | 22,521.70 | 172.91 | -0.76% |
| Nikkei 225 | 47,261.31 | 413.99 | 0.88% |
| NZX 50 Index | 13,311.70 | 34.71 | 0.26% |
| S&P 500 | 6,644.31 | 10.41 | -0.16% |
| S&P/ASX 200 | 8,964.30 | 4.40 | -0.05% |
| SSE Composite Index | 3,864.93 | 0.30 | -0.01% |